EDG-7500
DrugEDG-7500 is administered orally once daily
NCT Number: NCT06011317
The purposes of this Phase 1 study of EDG-7500 are to:
1. Learn about the safety of EDG-7500 after a single and multiple doses in healthy adults 2. Learn about how EDG-7500 is tolerated after a single and multiples doses in healthy adults 3. Evaluate the amount of EDG-7500 is in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-7500 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-7500 in the blood is similar for the suspension and tablet forms of EDG-7500 in healthy adults
Participants will receive a single or multiple doses of EDG-7500 or a placebo by mouth.
Looking for future studies?
Notify Me18 year–59 year
All sexes
Interventional
Phase 1
Celerion, Tempe, Arizona, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Additional protocol defined inclusion/exclusion criteria may apply.
EDG-7500 is administered orally once daily
Placebo is administered orally once daily
Time frame: Up to 25 days of monitoring
To assess the safety and tolerability of EDG-7500 when administered as single and multiple doses
Time frame: Up to 25 days of monitoring
Time to maximum concentration (Tmax)
Time frame: Up to 25 days of monitoring
Maximum observed concentration (Cmax)
Time frame: Up to 25 days of monitoring
Area under the concentration-time curve (AUC)
Time frame: Up to 25 days of monitoring
Terminal half-life (t1/2)
Time frame: Up to 25 days of monitoring
Renal clearance (CLr)
Edgewise Therapeutics, Inc.
Industry
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Healthy Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07470125
Healthy Subjects
Seoul, South Korea
View Trial DetailsNCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsNCT00761631
Healthy Subjects
Benton, Arkansas, United States
View Trial DetailsNCT02610465
Cardiac-Related Conditions, Healthy Subjects
Bethesda, Maryland, United States
View Trial Details